Point Biopharma Global Inc Reports Results For The Quarter Ended In March: Earnings Summary

POINT Biopharma Global

15/05/2023 14:31

* POINT Biopharma Global Inc  PNT.OQ  reported a quarterly
adjusted loss of 16 cents​​ per share for the quarter ended in
March. The mean expectation of ten analysts for the quarter was
for a loss of 31 cents per share.
    * Revenue was $9.55 million​; analysts expected zero. 
    * POINT Biopharma Global Inc's reported EPS for the quarter
was a
loss of 16 cents​.
    * The mean earnings estimate of analysts had fallen by
about 14.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * POINT Biopharma Global Inc shares had risen by 31.5% this
quarter and gained 31.1% so far this year.
    * The company reported a quarterly loss of $16.53 million.
    * Wall Street's median 12-month price target for POINT
Biopharma
Global Inc is $14.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.31          -0.16          Beat
 Dec. 31 2022      -0.26                         
 Sep. 30 2022      -0.28          -0.26          Beat
 Jun. 30 2022      -0.22          -0.27          Missed